CHICAGO--(BUSINESS WIRE)--Currently ramping up for Q2 production and distribution of its suite of products for the early screening and treatment of reproductive cancers, CytoCore, Inc. (OTCBB:CYCR) today noted a comprehensive new market report projecting 41 percent annual growth in the area of molecular diagnostics and screening in the United States alone, with a market potential of $92 billion projected by 2016.
